Benitec Biopharma Files Current Report

Ticker: BNTC · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1808898

Benitec Biopharma INC. 8-K Filing Summary
FieldDetail
CompanyBenitec Biopharma INC. (BNTC)
Form Type8-K
Filed DateOct 15, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001 B
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, regulatory

Related Tickers: BNTC

TL;DR

BNTC filed an 8-K on 10/15 for an event on 10/12. Standard disclosure.

AI Summary

Benitec Biopharma Inc. filed an 8-K on October 15, 2024, reporting an event on October 12, 2024. The filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company is incorporated in Delaware and its principal executive offices are located in Hayward, California.

Why It Matters

This 8-K filing indicates a routine update or disclosure from Benitec Biopharma Inc. to the SEC, providing information to investors and the public.

Risk Assessment

Risk Level: low — This filing is a standard current report and does not appear to contain any immediately alarming or significant new information.

Key Numbers

Key Players & Entities

FAQ

What specific event triggered this 8-K filing on October 12, 2024?

The filing does not specify the exact event that occurred on October 12, 2024, only that it is a current report filed on October 15, 2024.

What is the primary purpose of this 8-K filing for Benitec Biopharma Inc.?

The primary purpose is to serve as a current report of significant events or information as required by Section 13 or 15(d) of the Securities Exchange Act of 1934.

Where are Benitec Biopharma Inc.'s principal executive offices located?

Benitec Biopharma Inc.'s principal executive offices are located at 3940 Trust Way, Hayward, California, 94545.

What is the company's state of incorporation?

The company is incorporated in Delaware.

What is the SEC file number for Benitec Biopharma Inc.?

The SEC file number for Benitec Biopharma Inc. is 001-39267.

Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-10-15 08:07:52

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: October 15, 2024 /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing